Connecticut Wealth Management LLC Acquires 135 Shares of Boston Scientific Co. (NYSE:BSX)

Connecticut Wealth Management LLC increased its holdings in Boston Scientific Co. (NYSE:BSX) by 4.0% during the 4th quarter, HoldingsChannel reports. The firm owned 3,532 shares of the medical equipment provider’s stock after buying an additional 135 shares during the period. Connecticut Wealth Management LLC’s holdings in Boston Scientific were worth $315,000 at the end of the most recent reporting period.

Other large investors also recently bought and sold shares of the company. Ameritas Advisory Services LLC bought a new position in Boston Scientific during the fourth quarter valued at $658,000. Clear Harbor Asset Management LLC bought a new position in Boston Scientific during the fourth quarter valued at $251,000. Atomi Financial Group Inc. increased its position in Boston Scientific by 16.5% during the fourth quarter. Atomi Financial Group Inc. now owns 9,631 shares of the medical equipment provider’s stock valued at $860,000 after acquiring an additional 1,365 shares during the last quarter. Simon Quick Advisors LLC increased its position in Boston Scientific by 28.3% during the fourth quarter. Simon Quick Advisors LLC now owns 7,752 shares of the medical equipment provider’s stock valued at $692,000 after acquiring an additional 1,711 shares during the last quarter. Finally, Global Trust Asset Management LLC increased its position in Boston Scientific by 64.5% during the fourth quarter. Global Trust Asset Management LLC now owns 436 shares of the medical equipment provider’s stock valued at $39,000 after acquiring an additional 171 shares during the last quarter. Institutional investors own 89.07% of the company’s stock.

Insider Buying and Selling at Boston Scientific

In other Boston Scientific news, SVP Vance R. Brown sold 4,826 shares of the stock in a transaction dated Monday, April 21st. The shares were sold at an average price of $95.09, for a total transaction of $458,904.34. Following the completion of the sale, the senior vice president now directly owns 36,193 shares of the company’s stock, valued at approximately $3,441,592.37. This represents a 11.77% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, EVP Jeffrey B. Mirviss sold 4,675 shares of the stock in a transaction dated Monday, February 24th. The shares were sold at an average price of $104.25, for a total transaction of $487,368.75. Following the sale, the executive vice president now directly owns 28,454 shares of the company’s stock, valued at approximately $2,966,329.50. The trade was a 14.11% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 195,830 shares of company stock valued at $20,043,415. 0.50% of the stock is currently owned by insiders.

Boston Scientific Stock Down 0.2%

NYSE:BSX opened at $104.42 on Friday. Boston Scientific Co. has a 1-year low of $71.88 and a 1-year high of $107.17. The company has a 50-day moving average of $99.87 and a 200 day moving average of $97.16. The firm has a market cap of $154.48 billion, a PE ratio of 83.54, a price-to-earnings-growth ratio of 2.79 and a beta of 0.68. The company has a debt-to-equity ratio of 0.41, a current ratio of 1.08 and a quick ratio of 1.02.

Boston Scientific (NYSE:BSX) last released its quarterly earnings data on Wednesday, April 23rd. The medical equipment provider reported $0.75 earnings per share for the quarter, topping analysts’ consensus estimates of $0.67 by $0.08. Boston Scientific had a net margin of 11.07% and a return on equity of 17.80%. The company had revenue of $4.66 billion during the quarter, compared to analyst estimates of $4.57 billion. During the same period in the prior year, the firm earned $0.56 earnings per share. The firm’s revenue for the quarter was up 20.9% compared to the same quarter last year. As a group, research analysts anticipate that Boston Scientific Co. will post 2.85 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of research firms have weighed in on BSX. Needham & Company LLC boosted their price objective on shares of Boston Scientific from $113.00 to $115.00 and gave the company a “buy” rating in a research report on Thursday, April 24th. Evercore ISI boosted their price objective on shares of Boston Scientific from $110.00 to $112.00 and gave the company an “outperform” rating in a research report on Thursday, April 24th. Piper Sandler boosted their price objective on shares of Boston Scientific from $95.00 to $115.00 and gave the company an “overweight” rating in a research report on Monday, February 3rd. Erste Group Bank raised shares of Boston Scientific to a “strong-buy” rating in a research note on Thursday, May 8th. Finally, Royal Bank of Canada boosted their target price on shares of Boston Scientific from $116.00 to $120.00 and gave the company an “outperform” rating in a research note on Thursday, April 24th. Twenty-three research analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the stock. Based on data from MarketBeat, the company presently has an average rating of “Buy” and an average target price of $114.87.

Boston Scientific Company Profile

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.